TEST.V - FluroTech Ltd.

TSXV - TSXV Real Time Price. Currency in CAD
0.0000 (0.00%)
As of 03:50PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0100
Bid0.0050 x 0
Ask0.0050 x 0
Day's Range0.0050 - 0.0100
52 Week Range0.0050 - 0.0200
Avg. Volume19,075
Market Cap1.207M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    FluroTech Announces Proposed Business Combination with Renewable Geo Resources Ltd.

    Calgary, Alberta--(Newsfile Corp. - April 18, 2023) - FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) ("FluroTech" or the "Company") is pleased to announce that it has entered into a non-binding letter of intent ("LOI") dated April 14, 2023 to complete a business combination (the "Transaction") with Renewable Geo Resources Ltd. ("RGRL").Trading of the FluroTech's common shares has been halted in accordance with the policies of the TSX Venture Exchange (the "TSXV" or the "Exchange") and ...

  • CNW Group

    IIROC Trading Halt - TEST

    The following issues have been halted by IIROC:

  • GlobeNewswire

    FluroTech Ltd. Announces Sale of Shares in FluroTest Diagnostic Systems Ltd. and Option Cancellation

    CALGARY, Alberta, Jan. 03, 2023 (GLOBE NEWSWIRE) -- FluroTech Ltd. (“FluroTech” or the “Company”) (TSXV: TEST) announces that it has entered into a Share Purchase Agreement (“Agreement”) to sell all of the shares of FluroTest Diagnostic Systems Ltd., a wholly-owned subsidiary of the Company, to an arm’s length individual (the “Purchaser”). The Purchaser has agreed to pay total cash consideration of $1.00 in lawful Canadian currency. The completion of the transaction is effective December 31, 202

  • GlobeNewswire

    FluroTech Announces Strategic Exit of COVID-19 Pandemic Testing Business

    CALGARY, Alberta, Nov. 29, 2022 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”) announces that it has decided to exit the pandemic and emerging disease industry immediately and halt any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”). Due to declining rates of COVID-19 and the establishment of testing protocols by various governmental and commercial bodies, the demand for FluroTech’s PEDDP has signi